Boston Scientific Financial Statements (BSX)
|
|
|
|
Report date
|
|
|
23.02.2023 |
20.02.2024 |
21.02.2024 |
18.02.2025 |
17.02.2026 |
|
31.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
12 682 |
14 240 |
14 240 |
16 747 |
20 074 |
|
20 615 |
|
Operating Income, bln rub |
|
|
1 824 |
2 343 |
2 181 |
2 635 |
3 971 |
|
4 147 |
|
EBITDA, bln rub |
? |
|
2 741 |
3 620 |
3 453 |
3 938 |
3 733 |
|
4 763 |
|
Net profit, bln rub |
? |
|
698.0 |
1 593 |
1 593 |
1 854 |
2 886 |
|
3 553 |
|
|
OCF, bln rub |
? |
|
1 526 |
2 503 |
2 503 |
3 435 |
4 534 |
|
4 341 |
|
CAPEX, bln rub |
? |
|
612.0 |
800.0 |
800.0 |
790.0 |
876.0 |
|
899.0 |
|
FCF, bln rub |
? |
|
914.0 |
1 703 |
1 703 |
2 645 |
3 658 |
|
3 442 |
|
Dividend payout, bln rub
|
|
|
0.000 |
28.0 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
1.76% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
5 890 |
7 478 |
6 650 |
7 632 |
9 882 |
|
10 369 |
|
Cost of production, bln rub |
|
|
4 968 |
4 345 |
5 409 |
6 480 |
6 221 |
|
6 098 |
|
R&D, bln rub |
|
|
1 323 |
1 414 |
1 414 |
1 615 |
2 052 |
|
2 125 |
|
Interest expenses, bln rub |
|
|
464.0 |
265.0 |
272.0 |
387.0 |
349.0 |
|
357.0 |
|
|
Assets, bln rub |
|
|
32 470 |
35 136 |
35 136 |
39 395 |
43 673 |
|
44 351 |
|
Net Assets, bln rub |
? |
|
17 574 |
19 281 |
19 282 |
21 770 |
24 233 |
|
25 864 |
|
Debt, bln rub |
|
|
9 282 |
9 492 |
9 492 |
11 147 |
12 418 |
|
11 029 |
|
Cash, bln rub |
|
|
928.0 |
865.0 |
865.0 |
414.0 |
2 045 |
|
1 524 |
|
Net debt, bln rub |
|
|
8 354 |
8 627 |
8 627 |
10 733 |
10 373 |
|
9 505 |
|
|
Ordinary share price, rub |
|
|
46.3 |
57.8 |
57.8 |
89.3 |
95.4 |
|
56.0 |
|
Number of ordinary shares, mln |
|
|
1 431 |
1 453 |
1 453 |
1 472 |
1 480 |
|
1 485 |
|
|
Market cap, bln rub |
|
|
66 189 |
83 998 |
83 998 |
131 434 |
141 156 |
|
83 169 |
|
EV, bln rub |
? |
|
74 543 |
92 625 |
92 625 |
142 167 |
151 529 |
|
92 674 |
|
Book value, bln rub |
|
|
-1 249 |
-1 109 |
-1 108 |
-2 003 |
-1 068 |
|
268 |
|
|
EPS, rub |
? |
|
0.49 |
1.10 |
1.10 |
1.26 |
1.95 |
|
2.39 |
|
FCF/share, rub |
|
|
0.64 |
1.17 |
1.17 |
1.80 |
2.47 |
|
2.32 |
|
BV/share, rub |
|
|
-0.87 |
-0.76 |
-0.76 |
-1.36 |
-0.72 |
|
0.18 |
|
|
EBITDA margin, % |
? |
|
21.6% |
25.4% |
24.2% |
23.5% |
18.6% |
|
23.1% |
|
Net margin, % |
? |
|
5.50% |
11.2% |
11.2% |
11.1% |
14.4% |
|
17.2% |
|
FCF yield, % |
? |
|
1.38% |
2.03% |
2.03% |
2.01% |
2.59% |
|
4.14% |
|
ROE, % |
? |
|
3.97% |
8.26% |
8.26% |
8.52% |
11.9% |
|
13.7% |
|
ROA, % |
? |
|
2.15% |
4.53% |
4.53% |
4.71% |
6.61% |
|
8.01% |
|
|
P/E |
? |
|
94.8 |
52.7 |
52.7 |
70.9 |
48.9 |
|
23.4 |
|
P/FCF |
|
|
72.4 |
49.3 |
49.3 |
49.7 |
38.6 |
|
24.2 |
|
P/S |
? |
|
5.22 |
5.90 |
5.90 |
7.85 |
7.03 |
|
4.03 |
|
P/BV |
? |
|
-53.0 |
-75.7 |
-75.8 |
-65.6 |
-132.2 |
|
310.3 |
|
EV/EBITDA |
? |
|
27.2 |
25.6 |
26.8 |
36.1 |
40.6 |
|
19.5 |
|
Debt/EBITDA |
|
|
3.05 |
2.38 |
2.50 |
2.73 |
2.78 |
|
2.00 |
|
|
R&D/CAPEX, % |
|
|
216.2% |
176.8% |
176.8% |
204.4% |
234.2% |
|
236.4% |
|
|
CAPEX/Revenue, % |
|
|
4.83% |
5.62% |
5.62% |
4.72% |
4.36% |
|
4.36% |
|
| Boston Scientific shareholders |
